Leflunomide

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)0.97 [0.81, 1.16]0%3 studies14,378116not evaluable ROB
Major congenital malformations0.97 [0.81, 1.16]0%3 studies14,378116not evaluable ROB
4 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)2.04 [1.07, 3.90]0%2 studies10,86877not evaluable ROB
Low birth weight (< 2500g)1.06 [0.90, 1.25]0%2 studies23not evaluable ROB
2 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Caesarean--0 study
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
1 non statistically significant endpoints reported in only one study

Long term consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
2 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Early intrauterine death (< 22 weeks)1.09 [0.90, 1.32]0%2 studies17,747112not evaluable ROB
3 non statistically significant endpoints reported in only one study

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB